People living with Human Immunodefi ciency Virus/Acquired Immune Defi ciency Syndrome (HIV/AIDS) (PLH/PLHA) are increasing worldwide (29.8 million in 2001 and 36.9 million in 2014) mainly owing to the aversion of AIDS related deaths by effective antiretroviral therapy (ART). Although the prevalence is increasing, the new HIV infections decreased from 3.4 million in 2001 to 2 million in 2014, and AIDS-related deaths were decreased from the peak of 2.4 million in 2005 to 1.2 million in 2014. Implementation of ART with wide coverage and free access, especially in low-and middleincome countries is an important reason for the decline of AIDS-related deaths. Further, it is expected that the recent understanding in the mechanisms of latent infection and importance of reservoir could help to achieve a "functional cure" from HIV infection in near future.
Introduction
After three decades of intensive research on Human Immunodeficiency Virus (HIV), it remains as an important public health challenge worldwide, with signifi cant social and economic implications. 1 However, advances in the treatment of HIV infection have resulted in an ultimate shift in its epidemiology, from a deadly infectious disease to a chronic manageable condition. 2 Thus, the rate of incidence of Acquired Immune Defi ciency Syndrome (AIDS) that is the most severe clinical presentation of HIV infection have declined compared to that in 1990s. 3 In the year 2000, the Millennium Declaration Goal was established with special attention to control the global burden of HIV/AIDS by 2015 (MDG 6). After the declaration, enormous fund was released for the control of HIV infection, with the changing priority from time to time. Initially, the priority was given for primary prevention (prevention of HIV acquisition), and later for secondary prevention (prevention of HIV transmission), and recently the priority was shifted to the management of PLH/PLHA. Reportedly, from 2000 to 2014, about US$185.8 billion has been spent for the public health measures of HIV infection. 4 As we have reached the year 2015, herewith we analyze the trend of HIV prevalence and incidence along with AIDS-related deaths, and therapeutic/preventive milestones achieved in HIV research since 2001.
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Global Scenario of HIV/AIDS: Current Picture

Prevalence: People living with HIV
The global prevalence of HIV was gradually increased from 29.8 million in 2001 to 36.9 million in 2014 [ Figure 1 ]. The increase in HIV prevalence is mainly attributed to two factors -fi rst, the HIV causes persistent infection till death as it creates permanent reservoir in memory T H cells, and the second factor is the availability of antiretroviral therapy (ART) that signifi cantly improves the lifespan of PLH. Further, the occurrence of new HIV infections add up to the existing cases increases the PLH throughout the globe. Although the PLH are distributed worldwide, major proportion of them were living in the developing countries located in the southern Africa and Asia [ Figure 2 ].
Incidence: New HIV infections
The number of people who are newly infected with HIV is constantly declining in most parts of the world [ Figure 3 ]. According to the United Nations Programme on HIV and AIDS (UNAIDS), 4 about 2 million new HIV infections were documented in the year 2014, which is about 41.2% decline from the year 2001 (3.4 million). More specifi cally, in the past 4 years alone, new HIV infections declined by 16.7% (2.4 million in 2011) and it suggests that the current control measures implemented by public health authorities were working well and intensifying the control programs would give us better results.
Over the past decade, control of HIV incidence among children has been dramatic. In spite of having stringent preventive measures, about 0.22 million children were newly infected with HIV in the year 2014. However, this is 62.1% lower than the HIV incidence among children from the year 2001 (0.58 million). Similarly, 37.9% decrease was observed among adults (from 2.9 million in 2001 to 1.8 million in 2014). It is obvious that the stringent efforts taken by the UNAIDS is responsible for the decline in new HIV infections in many parts of the world including sub-Saharan Africa 5 and Asia 6,7 [ Figures 2 and 3 ]. However, the risk of second growth phase of the epidemic should always be kept in mind. 8 Hence, the intensifi ed prevention efforts need to be continued as long as HIV is not completely eliminated from the world.
AIDS-Related Deaths
Global AIDS-related deaths were peaked at 2.4 million in 2005 and decreased to 1.2 million in 2014 (40% decline) [ Figure 1 ]. It is well known that the AIDS-related deaths were primarily caused by opportunistic infections, which takes an opportunity of immunocompromised condition (caused by HIV infection) to infect the host, leading to fatal AIDS defi ning illnesses. But, in recent years, AIDS-related mortality was signifi cantly reduced, owing to an effective ART. Importantly, about 50% of all deaths among the PLH who have started ART are not due to AIDS. 9 However, tuberculosis, an AIDS defi ning illness, continues to be a major cause of morbidity and mortality in low-and middle-income countries. Nevertheless, the HIV-related tuberculosis mortality is 33% declined since 2004. 1, 4 
Management of HIV/AIDS: Highly Active Antiretroviral Therapy
A combination of antiretroviral regimens was developed in the late-1990s and introduced for clinical practice in the year 1997, which transformed HIV from a progressive fatal disease to a chronic manageable disease. 10 ART not only prevents AIDS-related illness and death, it also has the potential to signifi cantly reduce the risk of HIV transmission and the spread of tuberculosis. 11 From 1995 to 2013, ART had averted about 7.6 million AIDS-related deaths worldwide, including 4.8 million deaths in sub-Saharan Africa. 3 The management of HIV has now become simpler and cheaper than ever before, because of the increased access and wide availability of low-cost generic drugs and fi xed dose combinations of drugs. Based on the evidence, that the early initiation of ART provides better life to PLH, the World Health Organization guidelines 2 for ART initiation has been revised recently. The early initiation of ART decreases the risk of opportunistic infections as the immune system is not allowed to get compromised, thus causing a paradigm shift in the management of HIV from restoration of CD4 cells to preservation of CD4 cells. For this reason, the "test and treat strategy" has been adopted by many clinicians 12 in developed countries and it could become a worldwide norm for HIV management in the near future.
Because of the success of ART in attaining viral suppression, life expectancy of these patients has now become like a normal person. 13 However, toxic effects associated with the long-term use of ART causes premature ageing, 14 consequently many age-related issues were reported in this population. Therefore, future AIDS control programs should address these issues to make an effective public health policy.
Functional Cure for HIV: Not Far Away
Despite the great successes of ART in reducing AIDS-related morbidity and mortality, it is unable to cure HIV and it necessitates lifelong therapy. 9 The major limitations of ART is its inability to act on viral reservoirs and latently infected cells. Hence, the current theme of HIV research is mainly focused on fi nding ways for HIV cure to avoid drug toxicities and economic burden associated with lifelong ART.
A mechanism of HIV control similar to long-term nonprogressors (LTNP) has been observed among the HIV infected persons who had initiated ART during the acute phase of HIV infection. Interestingly, they had retained the HIV control for more than 10 years even after the discontinuation of ART at 3 years. 15 This observation suggests that early and prolonged ART might help some people to achieve a permanent control of viral replication without complete eradication called "functional cure" from HIV infection. Additional observations on the same mechanism of functional cure have been reported among HIV-infected infants. [16] [17] [18] However, another report states that the discontinuation of ART causes the rebound of viral load in an infant. 19 Hence, further research is needed to evaluate the effi cacy of the early initiation of ART in achieving functional cure from HIV infection.
Another approach was attempted to manually reactivate all latent viruses in the body, thus clearing the viral reservoir 20 and providing a functional cure. Although the study observed increased activation of latent virus, it does not document any reduction in viral reservoir. Hence, this approach is still in the preliminary stage of achieving a functional cure.
The Berlin patient case report is little more interesting and it is the fi rst documented report on HIV cure in medical literature. 21 The patient had received stem cell transplantation from a donor carrying a protective C-C chemokine receptor type 5 (CCR5) (co-receptor for HIV infection) mutation for the treatment of leukemia. Although his ART was stopped, there is no viral RNA detected in his plasma or tissue for more than 6 years. 21, 22 This case led to the process of developing a gene therapy to eliminate CCR5 in patient derived CD4 cells. 23 It is expected that the recent understanding in the mechanisms of latent infection 24 and importance of reservoir 25 might help to fi nd a way for "therapeutic cure" 26 or at least a "functional cure" from HIV infection in near future. 27, 28 Conclusion HIV infection still continues to be a major contributor to the global burden of disease, especially in sub-Saharan Africa. The incidence of HIV infections has been clearly documented to be declining across the globe. Further, ART has increased the lifespan of PLH and averted many AIDS-related deaths, and contributing to increase in the global prevalence of PLH. Recent understanding in the mechanisms of HIV infection might help to fi nd a way for therapeutic cure or at least a functional cure from HIV infection in near future.
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